Doxycycline Anhydrous

Doxycycline Anhydrous

SCHEMBL497163

C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP7 known ✓ P09237 1/20 0.69
MMP8 known ✓ P22894 1/20 0.69
MMP13 known ✓ P45452 1/20 0.69
TDP1 Q9NUW8 10/20 0.69
KDM4E B2RXH2 9/20 0.69
L3MBTL1 Q9Y468 7/20 0.69
USP2 O75604 6/20 0.69
MMP2 P08253 1/20 0.69
MMP3 P08254 1/20 0.69
ADORA1 P30542 1/20 0.69
ADRA1A P35348 1/20 0.69
HSD17B10 Q99714 6/20 0.68
HIF1A Q16665 3/20 0.68
TSHR P16473 1/20 0.68
RECQL P46063 7/20 0.67
PLA2G1B P04054 1/20 0.67
ATG4B Q9Y4P1 1/20 0.67
HPGD P15428 7/20 0.49
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Doxycycline Anhydrous SCHEMBL497165 1.00 TDP1 (0.69) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL17747966 1.00 TDP1 (0.69) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL229272 1.00 TDP1 (0.69) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL8709949 1.00 TDP1 (0.69) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL29151798 1.00 TDP1 (0.69) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL8709954 0.99 TDP1 (0.70) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL11417262 0.99 MMP2 (0.70) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL8683380 0.99 MMP2 (0.70) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL41883 0.99 MMP2 (0.70) TDP1KDM4EL3MBTL1USP2MMP2
Doxycycline Anhydrous SCHEMBL40834 0.99 TDP1 (0.70) TDP1KDM4EL3MBTL1USP2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029943-A1 Methods of Preparing Substituted Tetracyclines with Transition Metal-Based Chemistries TRUSTEES OF TUFTS COLLEGE (US) 2013-01-31 US disclosed
US-8106225-B2 Catalytically reacting a 7(9)- arene tetracycline diazonium salt or an iodotetracycline and a reactive substituent precursor, e.g., (substituted) alkenes, vinyl monomers, aromatics, carbon monoxide; carboxylation, esterification, amidation carbonylation, cyanation; anhydriding; imidation; bactericides TRUSTEES OF TUFTS COLLEGE (US) 2012-01-31 US disclosed
EP-1666454-B1 Methods of preparing substituted tetracyclines with transition metal-based chemistries TUFTS COLLEGE (US) 2011-09-07 EP disclosed
EP-2327686-A2 Methods of preparing substituted tetracyclines with transition metal-based chemistries TRUSTEES OF TUFTS COLLEGE (US) 2011-06-01 EP disclosed
EP-2327687-A2 Methods of preparing substituted tetracyclines with transition metal-based chemistries TRUSTEES OF TUFTS COLLEGE (US) 2011-06-01 EP disclosed
US-7696187-B2 Methods of preparing substituted tetracyclines with transition metal-based chemistries TRUSTEES OF TUFTS COLLEGE (US) 2010-04-13 US disclosed
US-20060166946-A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries TRUSTEES OF TUFTS COLLEGE (US) 2006-07-27 US disclosed
US-7067681-B2 Methods of preparing substituted tetracyclines with transition metal-based chemistries TRUSTEES OF TUFTS COLLEGE (US) 2006-06-27 US disclosed
EP-1666454-A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries TRUSTEES OF TUFTS COLLEGE (US) 2006-06-07 EP disclosed
EP-1666453-A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries TRUSTEES OF TUFTS COLLEGE (US) 2006-06-07 EP disclosed
EP-1240133-B1 METHODS OF PREPARING SUBSTITUTED TETRACYCLINES WITH TRANSITION METAL-BASED CHEMISTRIES TUFTS COLLEGE (US) 2006-04-19 EP disclosed
US-20050187198-A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries TRUSTEES OF TUFTS COLLEGE (US) 2005-08-25 US disclosed
US-20040033996-A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries PARATEK PHARMACEUTICALS, INC. 2004-02-19 US disclosed
WO-2003079983-A2 METHODS OF PREPARING SUBSTITUTED TETRACYCLINES WITH TRANSITION METAL-BASED CHEMISTRIES TRUSTEES OF TUFTS COLLEGE (US) 2003-10-02 WO disclosed
US-6617318-B1 7-substitted tetracyclines are effective against tetracycline-resistant E. coli, S. aureus and E. faecalis strains TRUSTEES OF TUFTS COLLEGE 2003-09-09 US disclosed
EP-1240133-A1 METHODS OF PREPARING SUBSTITUTED TETRACYCLINES WITH TRANSITION METAL-BASED CHEMISTRIES TRUSTEES OF TUFTS COLLEGE (US) 2002-09-18 EP disclosed
WO-2001019784-A1 METHODS OF PREPARING SUBSTITUTED TETRACYCLINES WITH TRANSITION METAL-BASED CHEMISTRIES TRUSTEES OF TUFTS COLLEGE (US) 2001-03-22 WO disclosed
EP-0137661-B1 A NEW PROCESS FOR THE PREPARATION OF ALPHA-6-DEOXY-TETRACYCLINES HOVIONE INTER LTD. (CH) 1989-11-02 EP disclosed
US-4597904-A STEREOSELECTIVE HYDROGENATION HOVIONE INTER LTD. (CH) 1986-07-01 US disclosed
EP-0137661-A2 A new process for the preparation of alpha-6-deoxy-tetracyclines HOVIONE INTER LTD. (CH) 1985-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187198-A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries TET1, TET3, DDT MMP7 2964/4885MMP8 3362/4885MMP13 3774/4885
US-20130029943-A1 Methods of Preparing Substituted Tetracyclines with Transition Metal-Based Chemistries TET1, TET3, DDT MMP7 2964/4885MMP8 3362/4885MMP13 3774/4885
US-20060166946-A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries TET1, TET3, DDT MMP7 2655/4885MMP8 2997/4885MMP13 3654/4885
US-20040033996-A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries TET1, TET3, DDT MMP7 2655/4885MMP8 2997/4885MMP13 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.